New Arthritis & Pain Compound

Create Awareness For a Novel Clinical Asset in a Competitive Category

Mission:

• Develop KOL awareness, network and segmentation
• Generate additional scientific evidence
• Maintain message consistency in all activities and communications

Key Issues:

• Pegylated compounds remain relatively unknown within the rheumatology and nephrology communities
• Clear definition of complex clinical settings for use of the drug
• Characterize efficacy and safety profile
• Identify unique value of compound relative existing therapies

Results:

• Phase III trial accrual on track for enrollment goal
• Epidemiology study led to abstract publication and increased KOL awareness and enthusiasm
• Rheumatology and nephrology communities actively engaged
• Effective segmentation of rheumatology and nephrology communities
• Differentiated from market competitors